AR
CLBT icon

Advisory Research’s Cellebrite CLBT Stock Holding History

Advisory Research’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-140,017
Closed -$1.21M – 190
2023
Q4 		$1.21M Sell
140,017
-80,318
-36% -$624K 0.19% 141
2023
Q3 		$1.69M Buy
220,335
+150,931
+217% +$1.13M 0.23% 126
2023
Q2 		$500K Buy
+69,404
New +$405K 0.06% 288

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return

Advisory Research's CLBT Position: Q1 2024 in Review

Advisory Research sold out of Cellebrite (CLBT) in Q1 2024, closing a stake of 140,017 shares — an estimated $1.21M sold.

Advisory Research first reported a position in CLBT in Q2 2023 and held it in 3 quarters. The position peaked at $1.69M in Q3 2023. 141 funds tracked by Wall St. Rank hold CLBT as of Q1 2024.

  • Advisory Research reported no remaining Cellebrite position as of Q1 2024 after selling out during the quarter.
  • Advisory Research sold 140,017 Cellebrite shares in Q1 2024, an estimated $1.21M.
  • Advisory Research first reported a position in Cellebrite in Q2 2023 and held it in 3 quarters.
  • Advisory Research's Cellebrite position peaked at $1.69M in Q3 2023.
  • 141 funds tracked by Wall St. Rank held Cellebrite as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.